

INFORMATION DISCLOSURE CITATION PTO-1449	Attorney Docket No.	Serial No.
	O/97277 US/D1	To be assigned
	Applicant	
	STIEKEMA ET AL.	
	Filing Date	Group
	November 2, 2001	To be assigned

1002 U.S. PTO
10/005793
11/02/01

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Translation
88783	AJ 0 084 999 A	08-03-1983	EP	
	AK			
	AL			
	AM			
	AN			
	AO			
	AP			
	AQ			

OTHER DOCUMENTS

88783	AR	BÉGUIN, S. ET AL.: "The Action of a Synthetic Pentasaccharide on Thrombin Generation in Whole Plasma", THROMBOSIS AND HEMOSTASIS, 61 (3) (1989), pages 397-401.
	AS	BARROWCLIFFE, T. ET AL.: "The Effect of Ca ²⁺ , phospholipid and Factor V on the anti-(Factor Xa) Activity of Heparin and Its High-Affinity Oligosaccharides", J. BIOCHEM, (1987) 243, pages 31-37.
	AT	EISENBERG, P. ET AL.: "Importance of Factor Xa in Determining the Procoagulant Activity of Whole-Blood Clots", J. CLIN. INVEST., Vol. 91, May 1993, pages 1877-1883.
	AU	MESSMORE ET AL.: "Clinical Efficacy of Heparin Fractions: Issues and Answers", CRIT. REV. IN CLIN. LAB. SCI., Vol. 23, Issue 2, 1986, pages 77-94.
	AV	LORMEAU ET AL.: "The Effect of the Synthetic Pentasaccharide SR90107/ORG31540 on Thrombin Generation Ex Vivo is Uniquely Due to ATIII-Medicated Neutralization of Factor Xa", THROMBOSIS AND HAEMOSTASIS, Vol. 74, No. 6, December 1995, pages 1474-1477.
88783	AW	VOGEL ET AL.: "Pentasaccharide and Orgaran® Arrest, whereas Heparin Delays Thrombus Formation in a Rat Arteriovenous Shunt", THROMBOSIS AND HAEMOSTASIS, Vol. 69, No. 1, 11 January 1993, pages 29-34.

Examiner <i>Silvia O'Neil Bana</i>	Date Considered <i>February 29, 2002</i>
---------------------------------------	---

INFORMATION DISCLOSURE CITATION PTO-1449	Attorney Docket No.	Serial No.
	O/97277 US/D1	To be assigned
	Applicant	
	STIEKEMA ET AL.	
	Filing Date	Group
	November 2, 2001	To be assigned


U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Translation

OTHER DOCUMENTS

<i>Sen03</i> 	AX	FREEDMAN, M.D.: "Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin", J. CLIN. PHARMACOL., Vol. 32, No. 7, 1992, pages 584-591.
	AY	CADROY ET AL.: "Antithrombotic Effects of Synthetic Pentasaccharide with High Affinity for Plasma Antithrombin III in Non-Human Primates", THROMBOSIS AND HAEMOSTASIS, Vol. 70, No. 4, 18 October 1993, pages 631-635.
	AZ	BERNAT ET AL.: "The Synthetic Pentasaccharide SR 90107/Org 31540 Enhances Tissue-Type Plasminogen Activator-Induced Thrombolysis in Rabbits", FIBRINOLYSIS, Vol. 10, No. 3, 1996, pages 151-157.
	BA	SCHIELE ET AL.: "Initial Experience of Sulphated Pentasaccharide, A Pure Factor Xa Inhibitor, in Coronary Angioplasty", CIRCULATION, Vol. 94, No. 8suppl., 1996, page I742, Abstract No. 4340. ABSTRACT ONLY.

Examiner <i>Liliana Ordoñez Bero</i>	Date Considered <i>February 20, 2002</i>
---	---